SAB Biotherapeutics, Inc. (SABS) vs Treace Medical Concepts, Inc. (TMCI)
A side-by-side comparison of SAB Biotherapeutics, Inc. and Treace Medical Concepts, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SABS
SAB Biotherapeutics, Inc.
$2.93HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TMCI
Treace Medical Concepts, Inc.
$4.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — SABS vs TMCI
growth of $100 · dividends reinvested · last 5ySABS -96.9% (-50.0%/yr)TMCI -82.5% (-29.4%/yr)TMCI compounded faster over this window
Log scale — wide-divergence pair
SABS TMCI
SABS vs TMCI: by the numbers
- •SABS is the larger company ($267M vs $259M market cap).
- •Both run net losses; SABS's is the smaller (0.00% vs -28.99% net margin).
Metrics side by side
Valuation
| Metric | SABS | TMCI |
|---|---|---|
| P/S ratio | N/A | 1.26 |
| P/B ratio | 1.24 | 3.83 |
Profitability
| Metric | SABS | TMCI |
|---|---|---|
| Gross margin | 0.00% | 79.45% |
| Operating margin | 0.00% | -26.17% |
| Net margin | 0.00% | -28.99% |
| ROE | -5.95% | -87.86% |
| ROIC | -31.62% | -37.64% |
Growth (annualized)
| Metric | SABS | TMCI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 21.44% |
| EPS CAGR (5Y) | -50.57% | N/A |
| Total return CAGR (5Y) | -50.16% | -29.41% |
Frequently asked
- How have SABS and TMCI total returns compared?
- Over the past 5 years, SABS delivered -50.16% and TMCI delivered -29.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
SAB Biotherapeutics ROETreace Medical Concepts ROESAB Biotherapeutics operating marginTreace Medical Concepts operating marginSAB Biotherapeutics revenue growthTreace Medical Concepts revenue growthSAB Biotherapeutics free cash flowTreace Medical Concepts free cash flow
SAB Biotherapeutics & Treace Medical Concepts appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.